The prevalence of salivary gland diseases has increased to 10% in the last decade. The structure of salivary gland pathology has also changed: if in the 80s, first of all, inflammatory processes prevailed and accounted for from 70 to 86%, and inflammatory-dystrophic and dystrophic diseases accounted for from 10 to 24%, then in our time the share of inflammatory-dystrophic diseases of the salivary glands increased to 20.4- 48.6%, and dystrophic to 44.3-57.6%. In terms of the frequency of occurrence, purulent-inflammatory processes in the salivary glands are in fifth place among all pathological processes in the maxillofacial region. From 9 to 12% of patients were hospitalized in the department of maxillofacial surgery for acute or exacerbation of chronic sialoadenitis, most often localized in the parotid salivary gland. With purulentinflammatory processes in the salivary glands, it is necessary to prolong the intake of antibacterial drugs for another 6-9 days after the passage of pronounced inflammatory processes in the gland to the stage of convalescence due to the presence of microflora contamination of the secreting epithelium, stagnation of infected saliva in the dilated ducts, difficult drainage of viscous saliva through narrow and long excretory ducts